Identifying founder mutations would enable us to examine specific loci in the screening of high‐risk subpopulations for inherited breast cancer without performing a full sequence analysis of BRCA1 and BRCA2. Founder mutations have previously been described for some population as in Ashkenazi Jewish population, 3% of individuals carried BRCA1 c.185delAG, BRCA1 c.5382insC or BRCA2 c.6174delT mutations (Wiesman et al., 2017). Here, BRCA2 is linked to breast carcinoma.